| acute heart failure | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| EVEREST Clinical Status , 2007 | vs placebo | | | | | EVEREST Outcome, 2007 | vs placebo | | | | | Udelson, 2007 | vs placebo | heart failure hospitalization 0.62 [0.38; 1.00] | | death 0.55 [0.21; 1.43] |
| Trial | Treatments | Patients | Method |
|---|
| EVEREST Clinical Status , 2007 | (n=-9) vs. (n=-9) | patients hospitalized with heart failure | Sample size: -9/-9 Primary endpoint: composite of global clinical status visual analog scale and body weight at short term FU duration: | | EVEREST Outcome, 2007 | (n=-9) vs. (n=-9) | patients hospitalized with heart failure | Sample size: -9/-9 Primary endpoint: FU duration: | | Udelson, 2007 | tolvaptan 30 mg/day (n=120) vs. placebo (n=120) | patients with HF and reduced systolic function | double blind Parallel groups Sample size: 120/120 Primary endpoint: left ventricular end-diastolic volume FU duration: 1 year |
|
| heart failure | All results are NS for efficacy | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| EVEREST Clinical Status , 2007 | vs placebo | | | | | EVEREST Outcome, 2007 | vs placebo | | | | | Udelson, 2007 | vs placebo | heart failure hospitalization 0.62 [0.38; 1.00] | | death 0.55 [0.21; 1.43] |
| Trial | Treatments | Patients | Method |
|---|
| EVEREST Clinical Status , 2007 | (n=-9) vs. (n=-9) | patients hospitalized with heart failure | Sample size: -9/-9 Primary endpoint: composite of global clinical status visual analog scale and body weight at short term FU duration: | | EVEREST Outcome, 2007 | (n=-9) vs. (n=-9) | patients hospitalized with heart failure | Sample size: -9/-9 Primary endpoint: FU duration: | | Udelson, 2007 | tolvaptan 30 mg/day (n=120) vs. placebo (n=120) | patients with HF and reduced systolic function | double blind Parallel groups Sample size: 120/120 Primary endpoint: left ventricular end-diastolic volume FU duration: 1 year |
|
